Michael Schmidt
Stock Analyst at Guggenheim
(2.34)
# 2,409
Out of 4,829 analysts
111
Total ratings
43.37%
Success rate
-2.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Reiterates: Neutral | $47 | $46.17 | +1.80% | 3 | May 12, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $12 → $10 | $1.86 | +439.08% | 4 | May 9, 2025 | |
| ONC BeiGene | Maintains: Buy | $348 → $350 | $228.63 | +53.09% | 3 | May 8, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $87 → $80 | $41.77 | +91.53% | 3 | May 8, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $30 → $10 | $3.02 | +231.13% | 1 | May 7, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $32 | $10.63 | +201.03% | 3 | May 6, 2025 | |
| ARVN Arvinas | Maintains: Buy | $32 → $16 | $6.54 | +144.65% | 5 | May 2, 2025 | |
| NBTX Nanobiotix | Maintains: Buy | $12 → $8 | $3.38 | +136.99% | 2 | Apr 4, 2025 | |
| ADCT ADC Therapeutics | Maintains: Buy | $10 → $7 | $1.30 | +439.00% | 4 | Mar 31, 2025 | |
| MRUS Merus | Reiterates: Buy | $109 | $42.69 | +155.36% | 5 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $1.75 | $0.30 | +475.09% | 3 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.86 | +104.08% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $25 | $7.65 | +226.80% | 2 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $92 | $60.66 | +51.67% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $32.47 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $20.03 | +124.66% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $5.38 | - | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $36.51 | +15.04% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.55 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $100.89 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $3.25 | +515.38% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.27 | +532.41% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.94 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.37 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.10 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.33 | +2,033.50% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $8.73 | +289.46% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.68 | +2,844.21% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.62 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.35 | +1,751.85% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $4.22 | +611.74% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.59 | +294.54% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.51 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $28.63 | +179.43% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.73 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.32 | +65.66% | 2 | Nov 7, 2017 |
SpringWorks Therapeutics
May 12, 2025
Reiterates: Neutral
Price Target: $47
Current: $46.17
Upside: +1.80%
Compass Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.86
Upside: +439.08%
BeiGene
May 8, 2025
Maintains: Buy
Price Target: $348 → $350
Current: $228.63
Upside: +53.09%
Revolution Medicines
May 8, 2025
Maintains: Buy
Price Target: $87 → $80
Current: $41.77
Upside: +91.53%
Relay Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $3.02
Upside: +231.13%
Syndax Pharmaceuticals
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $10.63
Upside: +201.03%
Arvinas
May 2, 2025
Maintains: Buy
Price Target: $32 → $16
Current: $6.54
Upside: +144.65%
Nanobiotix
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $3.38
Upside: +136.99%
ADC Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.30
Upside: +439.00%
Merus
Mar 28, 2025
Reiterates: Buy
Price Target: $109
Current: $42.69
Upside: +155.36%
Mar 26, 2025
Maintains: Buy
Price Target: $3 → $1.75
Current: $0.30
Upside: +475.09%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.86
Upside: +104.08%
Mar 20, 2025
Maintains: Buy
Price Target: $35 → $25
Current: $7.65
Upside: +226.80%
Mar 18, 2025
Downgrades: Neutral
Price Target: $92
Current: $60.66
Upside: +51.67%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $32.47
Upside: -
Mar 10, 2025
Initiates: Buy
Price Target: $45
Current: $20.03
Upside: +124.66%
Feb 26, 2025
Reiterates: Buy
Price Target: n/a
Current: $5.38
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $36.51
Upside: +15.04%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.55
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $100.89
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $3.25
Upside: +515.38%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.27
Upside: +532.41%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $28.94
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.37
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.10
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $0.33
Upside: +2,033.50%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $8.73
Upside: +289.46%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.68
Upside: +2,844.21%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $19.62
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $1.35
Upside: +1,751.85%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $4.22
Upside: +611.74%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $6.59
Upside: +294.54%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $3.51
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $28.63
Upside: +179.43%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $6.73
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.32
Upside: +65.66%